These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23879790)

  • 1. A transcellular assay to assess the P-gp inhibition in early stage of drug development.
    Taur JS; Schuck EL; Wong NY
    Drug Metab Lett; 2012; 6(4):285-91. PubMed ID: 23879790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
    Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
    Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
    Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
    Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
    Sato S; Tohyama K; Kosugi Y
    Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
    Wandel C; Kim R; Wood M; Wood A
    Anesthesiology; 2002 Apr; 96(4):913-20. PubMed ID: 11964599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.
    Crowe A; Wong P
    Toxicol Appl Pharmacol; 2003 Nov; 193(1):127-37. PubMed ID: 14613723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
    Bentz J; O'Connor MP; Bednarczyk D; Coleman J; Lee C; Palm J; Pak YA; Perloff ES; Reyner E; Balimane P; Brännström M; Chu X; Funk C; Guo A; Hanna I; Herédi-Szabó K; Hillgren K; Li L; Hollnack-Pusch E; Jamei M; Lin X; Mason AK; Neuhoff S; Patel A; Podila L; Plise E; Rajaraman G; Salphati L; Sands E; Taub ME; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yabut J; Yamagata T; Zhang L; Ellens H
    Drug Metab Dispos; 2013 Jul; 41(7):1347-66. PubMed ID: 23620485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506).
    Oda K; Nemoto H; Nagasaka Y; Kawamura A; Usui T
    Biopharm Drug Dispos; 2014 Apr; 35(3):135-44. PubMed ID: 24822242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH dependent uptake of loperamide across the gastrointestinal tract: an in vitro study.
    Crowe A; Wong P
    Drug Dev Ind Pharm; 2004 May; 30(5):449-59. PubMed ID: 15244080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
    Hochman JH; Pudvah N; Qiu J; Yamazaki M; Tang C; Lin JH; Prueksaritanont T
    Pharm Res; 2004 Sep; 21(9):1686-91. PubMed ID: 15497697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
    van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
    Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio.
    Nicolaï J; Chapy H; Gillent E; Saunders K; Ungell AL; Nicolas JM; Chanteux H
    Pharm Res; 2020 Aug; 37(9):175. PubMed ID: 32856111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein.
    Morishita H; Okawa K; Ishii M; Mizoi K; Ito MA; Arakawa H; Yano K; Ogihara T
    PLoS One; 2020; 15(10):e0232438. PubMed ID: 33119612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.
    Shirasaka Y; Suzuki K; Shichiri M; Nakanishi T; Tamai I
    Drug Metab Pharmacokinet; 2011; 26(2):171-9. PubMed ID: 21206133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK.
    Endo T; Kimura O; Sakata M
    Toxicol Appl Pharmacol; 2002 Dec; 185(3):166-71. PubMed ID: 12498733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization.
    Fischer H; Senn C; Ullah M; Cantrill C; Schuler F; Yu L
    J Pharmacol Exp Ther; 2021 Mar; 376(3):322-329. PubMed ID: 33288523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
    Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
    Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery.
    Kido Y; Nanchi I; Matsuzaki T; Watari R; Kiyohara H; Seki N; Okuda T
    Drug Metab Pharmacokinet; 2024 Jun; 56():101008. PubMed ID: 38663183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.